News | October 21, 2024
Senores Pharmaceuticals gets SEBI nod for IPO
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
The product is bioequivalent and therapeutically equivalent to the reference listed drug
The company also plans to boost its India presence by adding 1,500 beds in the next 2-3 years
The aggregate foreign investment, including investment from other foreign investors may be up to 90.1% shareholding in the company
Acquisition enhances Freenome's product portfolio, including autoantibody platform with additional biomarkers important in cancer detection
The issue with a face value of Rs 10 per equity share consists of a fresh issue of equity shares worth up to Rs 400 crore
The company will not receive any proceeds from the offer as all of it will go to the promoter selling shareholder.
The IPO is a complete OFS by existing shareholder Helix Investment Holdings
.jpg)
Evonik's six innovation growth fields are: Sustainable nutrition, healthcare solutions, advanced food ingredients, membranes, cosmetic solutions, and additive manufacturing
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Subscribe To Our Newsletter & Stay Updated
